{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:33:13Z","timestamp":1790530393824,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shaanxi Province Innovation Capability Support Plan","award":["2021PT-051"],"award-info":[{"award-number":["2021PT-051"]}]},{"name":"Shaanxi Province Innovation Capability Support Plan","award":["2025JC-GXPT-043"],"award-info":[{"award-number":["2025JC-GXPT-043"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 32270566"],"award-info":[{"award-number":["No. 32270566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03244-3","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:38:56Z","timestamp":1770287936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GRIN3A defines an immunosuppressive niche in advanced prostate cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Xinglin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhite","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kankan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"3244_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u201346. https:\/\/doi.org\/10.1001\/jama.2025.0228.","journal-title":"JAMA"},{"key":"3244_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"key":"3244_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer. 2024;23:183. https:\/\/doi.org\/10.1186\/s12943-024-02095-8.","journal-title":"Mol Cancer"},{"key":"3244_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"key":"3244_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032540","author":"S Gallo","year":"2023","unstructured":"Gallo S, Vitacolonna A, Crepaldi T. NMDA receptor and its emerging role in cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032540.","journal-title":"Int J Mol Sci"},{"key":"3244_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/145387","volume":"2013","author":"LA Kehoe","year":"2013","unstructured":"Kehoe LA, Bernardinelli Y, Muller D. GluN3A: an NMDA receptor subunit with exquisite properties and functions. Neural Plast. 2013;2013:145387. https:\/\/doi.org\/10.1155\/2013\/145387.","journal-title":"Neural Plast"},{"key":"3244_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101023","volume":"55","author":"M Bogaard","year":"2024","unstructured":"Bogaard M, Stromme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, et al. GRIN3A: a biomarker associated with a cribriform pattern and poor prognosis in prostate cancer. Neoplasia. 2024;55:101023. https:\/\/doi.org\/10.1016\/j.neo.2024.101023.","journal-title":"Neoplasia"},{"key":"3244_CR8","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35:4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"key":"3244_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa176","author":"FF Hu","year":"2021","unstructured":"Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbaa176.","journal-title":"Brief Bioinform"},{"key":"3244_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"3244_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311. https:\/\/doi.org\/10.1038\/nrc4016.","journal-title":"Nat Rev Cancer"},{"key":"3244_CR12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.7150\/thno.104135","volume":"15","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhao Z, Xie Q, Li H, Zhang C, He X, et al. JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4. Theranostics. 2025;15:1320\u201337. https:\/\/doi.org\/10.7150\/thno.104135.","journal-title":"Theranostics"},{"key":"3244_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010555","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Hu Y, Li H, Lu T, He X, Ma Y, et al. Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010555.","journal-title":"J Immunother Cancer"},{"key":"3244_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","volume":"62","author":"FH Schroder","year":"2012","unstructured":"Schroder FH, Hugosson J, Carlsson S, Tammela T, Maattanen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62:745\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.068.","journal-title":"Eur Urol"},{"key":"3244_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663. https:\/\/doi.org\/10.1038\/s41467-023-36325-2.","journal-title":"Nat Commun"},{"key":"3244_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15:9949. https:\/\/doi.org\/10.1038\/s41467-024-54364-1.","journal-title":"Nat Commun"},{"key":"3244_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123841","volume":"14","author":"S Koda","year":"2023","unstructured":"Koda S, Hu J, Ju X, Sun G, Shao S, Tang RX, et al. The role of glutamate receptors in the regulation of the tumor microenvironment. Front Immunol. 2023;14:1123841. https:\/\/doi.org\/10.3389\/fimmu.2023.1123841.","journal-title":"Front Immunol"},{"key":"3244_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310308","volume":"12","author":"T Yu","year":"2025","unstructured":"Yu T, Van der Jeught K, Zhu H, Zhou Z, Sharma S, Liu S, et al. Inhibition of glutamate-to-glutathione flux promotes tumor antigen presentation in colorectal cancer cells. Adv Sci. 2025;12:e2310308. https:\/\/doi.org\/10.1002\/advs.202310308.","journal-title":"Adv Sci"},{"key":"3244_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x.","journal-title":"Mol Cancer"},{"key":"3244_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3244_CR21","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","volume":"25","author":"S Goswami","year":"2024","unstructured":"Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024;25:2186\u201399. https:\/\/doi.org\/10.1038\/s41590-024-02015-4.","journal-title":"Nat Immunol"},{"key":"3244_CR22","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F. Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics. 2024;14:6913\u201334. https:\/\/doi.org\/10.7150\/thno.100555.","journal-title":"Theranostics"},{"key":"3244_CR23","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.cmet.2023.06.004","volume":"35","author":"C Xue","year":"2023","unstructured":"Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023;35:1304\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2023.06.004.","journal-title":"Cell Metab"},{"key":"3244_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad O, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22:43. https:\/\/doi.org\/10.1186\/s12943-023-01751-9.","journal-title":"Mol Cancer"},{"key":"3244_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells. Immunity. 2018;48:773-786 e775. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.018.","journal-title":"Immunity"},{"key":"3244_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/ITT.S507522","volume":"14","author":"Y Guo","year":"2025","unstructured":"Guo Y, Wang X, Zhang C, Chen W, Fu Y, Yu Y, et al. Tumor immunotherapy targeting B7\u2013H3: from mechanisms to clinical applications. Immunotargets Ther. 2025;14:291\u2013320. https:\/\/doi.org\/10.2147\/ITT.S507522.","journal-title":"Immunotargets Ther"},{"key":"3244_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175730","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27175730.","journal-title":"Molecules"},{"key":"3244_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399\u2013416. https:\/\/doi.org\/10.1038\/s41577-023-00973-8.","journal-title":"Nat Rev Immunol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03244-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:04:09Z","timestamp":1775649849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03244-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3244"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03244-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7574576\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were conducted between July 2024 and July 2025, in compliance with protocols approved by the Ethics Committee of Xijing Hospital, Air Force Medical University. Specifically, human prostate cancer tissue samples were collected under Approval No. KY20223403-1, and human blood samples were obtained under Approval No. KY2023250-C1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"128"}}